Cogan’s syndrome
ICD-10 M30.8 · ICD-11 4A44.Y

Treatment of Cogan’s Syndrome with Severe Systemic Manifestations

Cogan’s syndrome can extend well beyond its hallmark audiovestibular and ocular features. When severe systemic involvement is present, the clinical situation is more complex and the treatment approach correspondingly more intensive.

Clinical Scenario

This protocol applies to Cogan’s syndrome presenting with one or more of the following severe systemic manifestations:

Management of these manifestations is not standardly codified, reflecting both the rarity of Cogan’s syndrome and the heterogeneity of severe presentations.

Treatment Approach

In this setting, the approach centres on high-dose corticosteroid therapy — initiated intravenously before transitioning to oral treatment — combined with an immunosuppressive agent. The specific choice of immunosuppressant, the complete sequencing, and the clinical decision points are defined in the full protocol.

Full agent selection, dosing, and monitoring criteria are available in the structured protocol below.

References

DOI: 10.1016/j.revmed.2024.09.007

The treatment of other manifestations (constitutional symptoms, central nervous system involvement, cardiovascular involvement) is not codified.

In severe forms, treatment may primarily rely on high-dose steroid therapy (prednisone 1 mg/kg/day), preceded by methylprednisolone boluses (1 g/day for 3 days), and associated with an immunosuppressant and/or targeted therapy.

View source ↗